(Reuters) - Independent research committees overseeing the study, which is designed to gauge any increased risk of heart attack or stroke for people taking it, "are concerned about the ability of the study to continue" and are "considering what to do to prevent people from dropping out of the trial," the Times quoted Krall as saying.
Safety concerns about Avandia were stoked on Monday when The New England Journal of Medicine suggested in an analysis that Avandia, a treatment for Type 2 diabetes, carries an increased risk of heart attack, estimated in excess of 40 percent, in comparison to other diabetes drugs or placebos.
Read more at Reuters.com Government Filings News
Safety concerns about Avandia were stoked on Monday when The New England Journal of Medicine suggested in an analysis that Avandia, a treatment for Type 2 diabetes, carries an increased risk of heart attack, estimated in excess of 40 percent, in comparison to other diabetes drugs or placebos.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment